Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.60 |
| ▸ | JAK2 | O60674 | 6/20 | 0.60 |
| ▸ | TYK2 | P29597 | 3/20 | 0.60 |
| ▸ | JAK1 | P23458 | 7/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28364470 | 1.00 | JAK3 (0.60) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL29387805 | 1.00 | JAK3 (0.60) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL29387594 | 0.92 | JAK3 (0.65) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL21846882 | 0.92 | JAK3 (0.65) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL29388583 | 0.91 | JAK3 (0.60) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL21846884 | 0.91 | JAK3 (0.60) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL21846825 | 0.91 | JAK3 (0.68) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL29388306 | 0.91 | JAK3 (0.68) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL28364473 | 0.89 | JAK3 (0.53) | JAK3JAK2TYK2JAK1TTK | |
| SCHEMBL21846872 | 0.88 | JAK3 (0.61) | JAK3JAK2TYK2JAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2022-02-17 | — | — | US | disclosed |
| WO-2020052489-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | 中国药科大学 | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048914-A1 | PREPARATION FOR 6-AMINO-1H-PYRAZOLO[3,4-D]PYRIMIDINE-BASED JAK KINASE INHIBITOR AND APPLICATION THEREOF | JAK1, JAK3, SSB | JAK3 2/4885JAK2 5/4885TYK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.